Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Octreotide LAR, and Metronomic Capecitabine in Advanced Neuroendocrine Tumors
NCT01203306Phase 2Unknown
- Sponsor
- University of Turin
- Start
- Jan 2006
- Primary completion
- May 2009
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, Octreotide long-acting injection, capecitabine in neuroendocrine carcinoma (NEC), sponsored by University of Turin. Status: unknown.
02
Drugs
bevacizumabOctreotide long-acting injectioncapecitabine
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT01203306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01203306.